• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前蛋白转化酶枯草溶菌素/凯欣9型抗性R410S低密度脂蛋白受体突变:一种导致家族性高胆固醇血症的新机制。

The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.

作者信息

Susan-Resiga Delia, Girard Emmanuelle, Kiss Robert Scott, Essalmani Rachid, Hamelin Josée, Asselin Marie-Claude, Awan Zuhier, Butkinaree Chutikarn, Fleury Alexandre, Soldera Armand, Dory Yves L, Baass Alexis, Seidah Nabil G

机构信息

From the Laboratory of Biochemical Neuroendocrinology, Montreal, Quebec H2W 1R7, Canada.

the Department of Medicine, McGill University, Montreal, Quebec H3G 2M1, Canada.

出版信息

J Biol Chem. 2017 Feb 3;292(5):1573-1590. doi: 10.1074/jbc.M116.769430. Epub 2016 Dec 20.

DOI:10.1074/jbc.M116.769430
PMID:27998977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5290936/
Abstract

Familial hypercholesterolemia (FH) is characterized by severely elevated low density lipoprotein (LDL) cholesterol. Herein, we identified an FH patient presenting novel compound heterozygote mutations R410S and G592E of the LDL receptor (LDLR). The patient responded modestly to maximum rosuvastatin plus ezetimibe therapy, even in combination with a PCSK9 monoclonal antibody injection. Using cell biology and molecular dynamics simulations, we aimed to define the underlying mechanism(s) by which these LDLR mutations affect LDL metabolism and lead to hypercholesterolemia. Our data showed that the LDLR-G592E is a class 2b mutant, because it mostly failed to exit the endoplasmic reticulum and was degraded. Even though LDLR-R410S and LDLR-WT were similar in levels of cell surface and total receptor and bound equally well to LDL or extracellular PCSK9, the LDLR-R410S was resistant to exogenous PCSK9-mediated degradation in endosomes/lysosomes and showed reduced LDL internalization and degradation relative to LDLR-WT. Evidence is provided for a tighter association of LDL with LDLR-R410S at acidic pH, a reduced LDL delivery to late endosomes/lysosomes, and an increased release in the medium of the bound/internalized LDL, as compared with LDLR-WT. These data suggested that LDLR-R410S recycles loaded with its LDL-cargo. Our findings demonstrate that LDLR-R410S represents an LDLR loss-of-function through a novel class 8 FH-causing mechanism, thereby rationalizing the observed phenotype.

摘要

家族性高胆固醇血症(FH)的特征是低密度脂蛋白(LDL)胆固醇严重升高。在此,我们鉴定出一名FH患者,其低密度脂蛋白受体(LDLR)存在新的复合杂合突变R410S和G592E。该患者对最大剂量瑞舒伐他汀加依折麦布治疗反应一般,即使联合注射PCSK9单克隆抗体也是如此。我们旨在通过细胞生物学和分子动力学模拟来确定这些LDLR突变影响LDL代谢并导致高胆固醇血症的潜在机制。我们的数据表明,LDLR-G592E是2b类突变体,因为它大多无法离开内质网并被降解。尽管LDLR-R410S和LDLR-WT在细胞表面水平和总受体水平上相似,并且与LDL或细胞外PCSK9的结合能力相同,但LDLR-R410S对内体/溶酶体中外源PCSK9介导的降解具有抗性,并且相对于LDLR-WT,其LDL内化和降解减少。与LDLR-WT相比,有证据表明在酸性pH下LDL与LDLR-R410S的结合更紧密,LDL向晚期内体/溶酶体的递送减少,以及结合/内化LDL在培养基中的释放增加。这些数据表明LDLR-R410S与其负载的LDL一起循环利用。我们的研究结果表明,LDLR-R410S通过一种新的8类FH致病机制代表LDLR功能丧失,从而解释了观察到的表型。

相似文献

1
The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.前蛋白转化酶枯草溶菌素/凯欣9型抗性R410S低密度脂蛋白受体突变:一种导致家族性高胆固醇血症的新机制。
J Biol Chem. 2017 Feb 3;292(5):1573-1590. doi: 10.1074/jbc.M116.769430. Epub 2016 Dec 20.
2
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.pH值和低密度脂蛋白(LDL)对前蛋白转化酶枯草溶菌素9(PCSK9)依赖性低密度脂蛋白受体调节的影响。
J Biol Chem. 2007 Jul 13;282(28):20502-12. doi: 10.1074/jbc.M701634200. Epub 2007 May 10.
3
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.分泌性前体蛋白转化酶PCSK9的细胞运输及其对低密度脂蛋白受体(LDLR)的依赖性。
Traffic. 2007 Jun;8(6):718-32. doi: 10.1111/j.1600-0854.2007.00562.x. Epub 2007 Apr 25.
4
Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.家族性高胆固醇血症患者的前蛋白转化酶枯草溶菌素/柯萨奇蛋白酶 9 血清水平表明,前蛋白转化酶枯草溶菌素/柯萨奇蛋白酶 9 通过 LDL 受体非依赖途径从血浆中清除。
Transl Res. 2012 Aug;160(2):125-30. doi: 10.1016/j.trsl.2012.01.010. Epub 2012 Jan 31.
5
A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.PCSK9 前肽域中的一个瞬态两亲性螺旋促进与低密度脂蛋白颗粒的结合。
J Biol Chem. 2020 Feb 21;295(8):2285-2298. doi: 10.1074/jbc.RA119.010221. Epub 2020 Jan 16.
6
Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.血浆 PCSK9 水平升高对非家族性高胆固醇血症和杂合子家族性高胆固醇血症患者同样有害,与低密度脂蛋白受体缺陷无关。
J Am Coll Cardiol. 2014 Jun 10;63(22):2365-73. doi: 10.1016/j.jacc.2014.02.538. Epub 2014 Mar 12.
7
Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.载脂蛋白 B 代谢途径基因 PCSK9 中 R46L 错义突变对家族性高胆固醇血症杂合子患者的血清总胆固醇水平影响较小。
Clin Chim Acta. 2010 Feb;411(3-4):229-33. doi: 10.1016/j.cca.2009.11.008. Epub 2009 Nov 13.
8
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.纯合子家族性高胆固醇血症患者携带相同的 LDLR(低密度脂蛋白受体)突变,其表达可变:对依洛尤单抗疗效的影响。
Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):592-598. doi: 10.1161/ATVBAHA.117.310217. Epub 2017 Dec 28.
9
Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.具有低密度脂蛋白受体(LDLR)突变的前蛋白转化酶枯草杆菌蛋白酶/kexin 9 V4I变体改变家族性高胆固醇血症的表型。
J Clin Lipidol. 2016 May-Jun;10(3):547-555.e5. doi: 10.1016/j.jacl.2015.12.024. Epub 2016 Jan 6.
10
Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.由前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)功能获得性突变引起的纯合子家族性高胆固醇血症的基因型和表型特征。
Atherosclerosis. 2014 Sep;236(1):54-61. doi: 10.1016/j.atherosclerosis.2014.06.005. Epub 2014 Jun 26.

引用本文的文献

1
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.靶向前蛋白转化酶枯草溶菌素 9(PCSK9):从实验室到临床。
Signal Transduct Target Ther. 2024 Jan 8;9(1):13. doi: 10.1038/s41392-023-01690-3.
2
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk.心血管药物的药物基因组学与动脉粥样硬化血栓形成、血栓栓塞和动脉粥样硬化风险
Genes (Basel). 2023 Nov 9;14(11):2057. doi: 10.3390/genes14112057.
3
Endocrine Regulation of Microvascular Receptor-Mediated Transcytosis and Its Therapeutic Opportunities: Insights by PCSK9-Mediated Regulation.微血管受体介导的转胞吞作用的内分泌调节及其治疗机会:PCSK9介导的调节见解
Pharmaceutics. 2023 Apr 18;15(4):1268. doi: 10.3390/pharmaceutics15041268.
4
Proprotein convertase subtilisin/kexin type 9 inhibitor non responses in an adult with a history of coronary revascularization: A case report.一名有冠状动脉血运重建病史的成年人对前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂无反应:病例报告。
World J Clin Cases. 2022 Jul 6;10(19):6728-6735. doi: 10.12998/wjcc.v10.i19.6728.
5
Identification of New Genetic Determinants in Pediatric Patients with Familial Hypercholesterolemia Using a Custom NGS Panel.使用定制 NGS .panel 鉴定家族性高胆固醇血症儿科患者中的新遗传决定因素。
Genes (Basel). 2022 Jun 1;13(6):999. doi: 10.3390/genes13060999.
6
The Multifaceted Biology of PCSK9.载脂蛋白 C-III(APOC3)基因的多态性与甘油三酯水平升高和心血管疾病(CVD)风险增加有关。
Endocr Rev. 2022 May 12;43(3):558-582. doi: 10.1210/endrev/bnab035.
7
Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9.抵抗素通过 PCSK9 调节人胎盘外植体中的低密度脂蛋白胆固醇摄取。
Reprod Sci. 2022 Nov;29(11):3242-3253. doi: 10.1007/s43032-022-00943-w. Epub 2022 Apr 25.
8
Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies.肝脏感应回路调节 PCSK9 分泌以响应抑制性抗体。
J Am Coll Cardiol. 2021 Oct 5;78(14):1437-1449. doi: 10.1016/j.jacc.2021.07.056.
9
Montreal-FH-SCORE Predicts Coronary Artery Calcium Score in Patients With Familial Hypercholesterolemia.蒙特利尔 - FH评分可预测家族性高胆固醇血症患者的冠状动脉钙化积分
CJC Open. 2020 Sep 14;3(1):41-47. doi: 10.1016/j.cjco.2020.09.007. eCollection 2021 Jan.
10
Proteostasis Regulation in the Endoplasmic Reticulum: An Emerging Theme in the Molecular Pathology and Therapeutic Management of Familial Hypercholesterolemia.内质网中的蛋白质稳态调节:家族性高胆固醇血症分子病理学与治疗管理中的一个新兴主题
Front Genet. 2020 Sep 23;11:570355. doi: 10.3389/fgene.2020.570355. eCollection 2020.

本文引用的文献

1
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.前蛋白转化酶枯草杆菌蛋白酶/克新蛋白酶9型(PCSK9)单域抗体是低密度脂蛋白受体降解的强效抑制剂。
J Biol Chem. 2016 Aug 5;291(32):16659-71. doi: 10.1074/jbc.M116.717736. Epub 2016 Jun 8.
2
Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain.前蛋白转化酶枯草溶菌素9(PCSK9)诱导低密度脂蛋白受体(LDLR)降解的运输动力学:聚焦于人类PCSK9突变和C末端结构域
PLoS One. 2016 Jun 9;11(6):e0157230. doi: 10.1371/journal.pone.0157230. eCollection 2016.
3
Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor.肝细胞通过低密度脂蛋白受体从循环中清除脂多糖。
PLoS One. 2016 May 12;11(5):e0155030. doi: 10.1371/journal.pone.0155030. eCollection 2016.
4
PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.在小鼠中,前蛋白转化酶枯草溶菌素9(PCSK9)缺乏揭示了低密度脂蛋白(LDL)和极低密度脂蛋白(VLDL)受体在性别和组织特异性的亚细胞分布。
J Lipid Res. 2015 Nov;56(11):2133-42. doi: 10.1194/jlr.M061952. Epub 2015 Aug 31.
5
Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.淀粉样前体样蛋白2和sortilin不调节前蛋白转化酶枯草溶菌素9介导的低密度脂蛋白受体降解,但它们相互作用。
J Biol Chem. 2015 Jul 24;290(30):18609-20. doi: 10.1074/jbc.M115.647180. Epub 2015 Jun 17.
6
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.依折麦布联合他汀类药物治疗急性冠脉综合征。
N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.
7
Evolocumab (AMG 145) for primary hypercholesterolemia.依洛尤单抗(AMG 145)用于原发性高胆固醇血症。
Expert Rev Cardiovasc Ther. 2015 May;13(5):477-88. doi: 10.1586/14779072.2015.1030395. Epub 2015 Mar 31.
8
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.依洛尤单抗降低血脂和心血管事件的疗效和安全性。
N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15.
9
Functional characterization and classification of frequent low-density lipoprotein receptor variants.常见低密度脂蛋白受体变异体的功能特性与分类
Hum Mutat. 2015 Jan;36(1):129-41. doi: 10.1002/humu.22721. Epub 2014 Nov 27.
10
Low density lipoprotein receptor class A repeats are O-glycosylated in linker regions.低密度脂蛋白受体A类重复序列在连接区进行O-糖基化修饰。
J Biol Chem. 2014 Jun 20;289(25):17312-24. doi: 10.1074/jbc.M113.545053. Epub 2014 May 5.